Delivering innovative biomarker assays for Immuno-oncology translational research & clinical trials.
Date: Friday July 12th 2019
Time: 9:00am – 12:30pm ET
Location: Massachusetts Biotechnology Council 300 Technology Square, 8th Floor, Collaboration Room, Cambridge, MA 02139
Description: One of the biggest challenges in immunotherapy area is to find accurately which patients will benefit from a therapy or a combination of therapies. To help drug developers getting this information, the assessment of biomarkers through clinical research studies represent a key step. During this seminar, you will learn about HalioDx innovative IMMUNOGRAM platform combined with high level immuno-oncology expertise, providing to biotech and pharma partners a unique solution to get meaningful and actionable data through biomarker testing.
- Breakfast, Registration and Networking session
- Introduction by Thomas Colarusso, HalioDx
- Innovative technologies for Immune Biomarkers assessment
- HALO® Image Analyis Platform, a comprehensive solution for digital pathology, by Douglas Bowman, VP Business Development Indica Labs
- Brightplex®, a powerful multiplexing technology to assess complex immune phenotypes in the tumor microenvironment, by Jacques Fieschi, VP, R&D HalioDx
- IMMUNOGRAM, a comprehensive platform dedicated to Pharma Clinical Research programs, by Jacques Fieschi
- Question and Answers session
A Continental Breakfast buffet will be served at the beginning of the seminar
There is a parking garage located at 800 Technology Square, Cambridge, MA 02139
If you are interested in learning more, please contact our Business Development contact at thomas.colarusso(at)haliodx(dot)com
Douglas Bowman, VP Business Development Indica Labs
Doug is responsible for Indica Labs’ Pharma Services group which provides quantitative histopathology image analysis services to support customer’s preclinical and clinical biomarker assays. He also develops strategic business relationships to support the services business. Prior to Indica Labs, he spent 12+ years at Takeda Pharmaceuticals where he developed and expanded the tissue-based imaging capabilities to support early discovery, translational, and clinical programs. He was a key member of a team responsible for building a digital pathology laboratory that integrated LIMs, immunohistochemistry, slide scanners, and quantitative image analysis in an automated workflow. Doug has a BSE in biomedical and electrical engineering from Duke University.
Jacques Fieschi, VP, R&D HalioDx
Jacques Fieschi is in charge of the Research & Development Department of HalioDx that develops tests and methods to grow the pipeline of the Diagnostic and Pharma Business Units of the company. Previously, he occupied different positions within the Immunodiagnostic branch of Beckman-Coulter, leading the development of several immunoassays, then joined QIAGEN Marseille as Head of Program Management. Jacques Fieschi received his Ph.D. degree in immunology from Aix-Marseille University.